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Abstract
Liver transplantation alone for unresectable hilar cholangiocarcinoma (CCA) is fraught with frequent recurrence and poor
long-term survival. The Mayo Clinic developed a novel therapeutic protocol combining neoadjuvant chemoradiation and
orthotopic liver transplantation (OLT) in 1993 to treat patients with unresectable hilar CCA or CCA arising in the setting of
PSC. Aim. We recently reviewed our experience over the past 14 years with the specific aim to evaluate the long-term
outcomes of CCA patients treated according to our study protocol. Methods. We analyzed data from all patients enrolled in
the Mayo Clinic liver transplant protocol since 1993. Statistical data analysis of recurrence and survival rates was performed
using the Kaplan-Meier method. Results. 148 patients were enrolled in the protocol. Of 90 patients who completed
neoadjuvant therapy and subsequent OLT, 71 are alive and 19 have died  only 8 due to recurrent CCA. Nineteen patients
are awaiting OLT and 39 were removed from the protocol owing to disease progression or death. Overall, 1-, 3-, and 5-year
patient survival was 82%, 63%, and 55%, respectively; 1-, 3-, and 5-year survival after OLT was 90%, 80%, and 71%.
Conclusions. Neoadjuvant chemoradiation and OLT achieves significantly lower recurrence and higher long-term survival
rates than resection, OLT alone, or medical treatment in hilar CCA. Additional experience at independent transplant
centers is necessary to confirm these encouraging results, address the role of neoadjuvant therapy and liver transplantation
versus conventional resection, determine appropriate inclusion/exclusion criteria, and define the risk of disease progression
while awaiting transplantation.
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Introduction
Cholangiocarcinoma (CCA) may occur as an intra-
hepatic mass or as an obstructing tumor involving
the major intrahepatic and/or extrahepatic bile ducts.
Intrahepatic CCA is best treated by liver resection.
Liver transplantation for intrahepatic CCA is fraught
with rapid metastases and has been abandoned at
most centers [1].
Liver transplantation has no role in the treatment
of periductal CCA that is limited to the extrahepatic
duct below the bifurcation of the common hepatic
duct. These tumors are best treated by surgical
resection.
Surgical resection has been the mainstay of treat-
ment for periductal CCA arising in the hilus of the
liver. Unfortunately, extensive perineural and lym-
phatic invasion, bilateral liver involvement, and vas-
cular encasement frequently preclude potentially
curative resection [2]. CCA arising in the setting of
PSC is even more difficult to treat either due to
advanced tumor stage or liver disease, and resection in
the setting of PSC is essentially futile [3].
Liver transplantation alone
Orthotopic liver transplantation appeared promising
as it would easily achieve a tumor-free margin within
the liver, accomplish a radical resection, and treat
underlying PSC when present. Despite this sound
rationale, actual experiences have been very poor. The
Cincinnati Transplant Tumor Registry reported 28%
5-year survival with a 51% tumor recurrence rate [1].
Eighty-four percent of the recurrences were detected
within 2 years, with 47% occurring in the liver
allograft and 30% in the lungs. Incidentally detected
CCA fared no better than other tumors, and adjuvant
therapy was not associated with survival.
Three recent multicenter series corroborate the
registry findings. A Scandinavian series reported
30% 5-year survival for patients with early stage
(Received 5 February 2008; accepted 14 February 2008)
ISSN 1365-182X print/ISSN 1477-2574 online # 2008 Taylor & Francis
DOI: 10.1080/13651820801992542
Correspondence: Charles Rosen, Department of Surgery, Mayo Clinic in Rochester, 200 First Street, S.W. Rochester, MN 55905, USA. Tel: 1 507 284 01
61. E-mail: rosen.charles@mayo.edu
HPB, 2008; 10: 186189
CCA (no mass lesions) arising in the setting of PSC
[4]. The Spanish liver transplant centers reported
a similar experience, 30% 3-year survival for 36
patients [5]. Even CCA incidentally found in liver
explants portended a poor prognosis, as reported in a
multicenter Canadian experience [6]. Three-year
survival for 10 patients was identical to the Spanish
series  30%, and the median time to recurrence was
26 months.
The University of Pittsburgh pioneered a radical
approach with cluster abdominal transplantation,
but results were equally poor, i.e. 20% 3-year survival
and a 57% recurrence rate [7]. As a result of these
experiences, CCA has become widely recognized as a
contraindication to liver transplantation [8].
Neoadjuvant therapy and liver transplantation
Despite the overall poor results with liver transplanta-
tion alone, a few patients with negative margins
and absence of regional lymph node metastases did
do well after transplantation [9]. In addition, a small
group of patients at the Mayo Clinic treated with
primary radiotherapy and chemosensitization alone
(without resection) had 22% 5-year survival [10].
Based on the known palliative efficacy of radio-
therapy for CCA and the knowledge that CCA
resection failures are usually due to locoregional
recurrence rather than distant metastases [11], the
transplant team at the University of Nebraska pio-
neered a strategy of high-dose neoadjuvant bra-
chytherapy and 5-fluorouracil (5-FU) followed by
liver transplantation [12]. Although there were sig-
nificant complications attributed to use of high-dose
brachytherapy, early results were promising with
regard to locoregional control of cancer.
The Mayo Clinic adopted this concept with the
development of a similar neoadjuvant therapy/liver
transplant protocol in 1993. The protocol combined
the benefits of radiotherapy, chemosensitization, liver
transplantation, and appropriate patient selection for
patients with localized, unresectable hilar CCA. Pre-
liminary results for 11 patients reported in 2000 were
encouraging [13], and an update in 2004 reported
82% 5-year survival for 28 patients [14].
Mayo clinic protocol
The Mayo Clinic protocol involves careful selection of
patients with early stage CCA which is either un-
resectable or arising in the setting of underlying PSC.
Vascular encasement of the hilar vessels is not a
contraindication to transplantation. The upper limit
of tumor size is 3 cm, and there must be no evidence
of intra- or extrahepatic metastases. The protocol
specifically excludes patients with intrahepatic CCA
or gallbladder involvement.
Neoadjuvant therapy includes 4000 to 4500 cGy
administered by external beam, followed by 2000 to
3000 cGy transcatheter irradiation with iridium.
5-FU is given during the radiation treatment and
capecitabine is then administered until transplanta-
tion. Prior to transplantation, patients undergo a
staging abdominal exploration. Regional lymph node
metastases, peritoneal metastases, or locally extensive
disease preclude transplantation.
Mayo Clinic experience
One-hundred-and-forty-eight patients have begun
neoadjuvant therapy at the Mayo Clinic Rochester
since 1993, and 90 have had favorable findings at
the staging operation and subsequent liver transplan-
tation [unpublished data through October 2007].
Five-year actuarial survival for all patients that began
neoadjuvant therapy is 55%, and 5-year survival after
transplantation is 71%.
Factors that adversely affect prognosis are: older
patient age, prior cholecystectomy, CA-19.9 100 at
time of transplantation, visible mass on cross-
sectional imaging, and prolongation of waiting time
[15]. Explanted livers with residual cancer 2 cm,
high tumor grade, and/or perineural invasion are also
associated with tumor recurrence.
Controversy and discussion
Despite the extensive Mayo Clinic experience, liver
transplantation for CCA raises several controversial
issues: 1) Does liver transplantation following neoad-
juvant therapy have efficacy in the treatment of
CCA? 2) Do results warrant use of a donor liver for
patients with CCA? 3) Would transplantation with
neoadjuvant therapy be better treatment than resec-
tion for patients with potentially resectable disease?
and 4) What is the appropriate prioritization for
patients with CCA awaiting a deceased donor liver?
Efficacy of neoadjuvant therapy and transplantation
is demonstrated by comparing results with the natural
history of the disease. Untreated CCA has a 5070%
mortality rate within 12 months [16,17], which is
much lower than 55% 5-year survival for patients
entered in the Mayo Clinic protocol and 71% 5-year
survival after transplantation. However, only two
centers (Mayo Clinic and the University of Nebraska)
have published their experiences with this approach.
Confirmation of efficacy by other centers is necessary
prior to widespread adoption of this approach to the
treatment of hilar CCA.
The Mayo Clinic reported that neoadjuvant therapy
and liver transplantation achieves results similar to
transplantation for other chronic liver diseases and
hepatocellular carcinoma [14]. Thus, it would seem
appropriate that patients with CCA be considered
appropriate recipients for scarce donor livers. Indeed,
neoadjuvant therapy and transplantation is their only
opportunity for prolonged survival.
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The Mayo Clinic also reported that survival after
transplantation in patients with unresectable CCA or
CCA arising in the setting of PSC exceeded survival
in patients who underwent resection [18]. However,
there were significant differences between the two
groups; the transplant group was younger and more
likely to have underlying PSC (and perhaps earlier
stage disease despite being unresectable). Moreover,
Neuhaus et al. have reported 60% 5-year survival
(after censoring perioperative mortality) following
resection with portal vein resection and reconstruc-
tion, which is a significant improvement compared to
prior experiences with resection [19].
Liver transplantation following neoadjuvant ther-
apy does not appear to be an inferior cancer operation
compared to resection. Transplantation affords a
more radical extirpation of CCA than does resection
with absolute certain avoidance of hepatic duct
margin involvement. Liver transplantation is techni-
cally feasible despite aggressive neoadjuvant therapy,
which is necessary to achieve success. Indeed, neoad-
juvant therapy and transplantation may be considered
a ‘‘new paradigm’’ in the treatment of CCA [20].
Prioritization for deceased donor liver allocation is
highly controversial and has been discussed in detail
by an international group of transplant surgeons and
physicians [MELD Exception Study Group, Chicago,
12 March 2006]. The MELD Exception Study
Group concluded that current data justify priority
for patients enrolled in clinical trials provided: 1)
Transplant centers submit formal patient care proto-
cols to the UNOS Liver and Intestinal Committee; 2)
candidates satisfy accepted diagnostic criteria for
CCA and be considered unresectable on the basis
of technical considerations or underlying liver disease
(e.g. PSC); 3) tumor mass, when visible on cross-
sectional imaging studies, be less than 3 cm in
diameter; 4) imaging studies to assess patients for
intra- and extrahepatic metastases be repeated prior
to interval score increases; 5) regional hepatic lymph
node involvement and the peritoneal cavity be
assessed by operative staging after completion of
neoadjuvant therapy and prior to transplantation;
and 6) transperitoneal aspiration or biopsy of the
primary tumor be avoided because of the high risk of
tumor seeding associated with these procedures [21].
Conclusions
The results of liver transplantation alone for either
intrahepatic or hilar CCA are poor; patient survival is
less than 30% at 5 years. Widespread experience
(registry data, multicenter and single center reports)
warrants avoidance of liver transplantation for
patients known to have CCA. Indeed, hilar and
intrahepatic CCA are well accepted contraindications
for liver transplantation.
The University of Nebraska and the Mayo Clinic
have demonstrated that excellent survival can be
obtained for highly selected patients with early stage
hilar CCA treated with aggressive neoadjuvant ther-
apy prior to liver transplantation. The combination
of neoadjuvant therapy, operative staging to rule out
regional metastases, and liver transplantation has
achieved remarkable success for selected patients
with early stage unresectable CCA and CCA arising
in the setting of primary sclerosing cholangitis. Addi-
tional experience at independent transplant centers
will be necessary to confirm these encouraging results,
address the role of neoadjuvant therapy and liver
transplantation versus conventional resection, deter-
mine appropriate inclusion/exclusion criteria, and
define the risk of disease progression while awaiting
transplantation.
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